Why the study?
Long non-coding RNAs play vital roles in diabetic nephropathy, but the potential role and underlying molecular mechanisms of long non-coding RNA MEG3 were not fully understood.
Does long non-coding RNA MEG3 promote fibrosis and inflammatory response in diabetic nephropathy?
Does long non-coding RNA MEG3 promote fibrosis and inflammatory response in diabetic nephropathy?
The study identifies the MEG3/miR-181a/Egr-1/TLR4 axis as a key regulatory pathway in the progression of diabetic nephropathy, offering potential new therapeutic targets.
Answers are grounded in this paper and cite their sources.
Should not yet change DN practice; leaves open MEG3-miR-181a targeting for future validation.
Long non-coding RNAs (lncRNAs) play vital roles in diabetic nephropathy (DN). This research aimed to study the potential role and underlying molecular mechanisms of long non-coding RNA MEG3 in DN. We found that MEG3 was upregulated in DN in vivo and in vitro and could enhance cell fibrosis and inflammatory response in DN. MEG3 functioned as an endogenous sponge for miR-181a in mesangial cells (MCs) via direct targeting and in an Ago2-dependent manner. MiR-181a inhibition promoted MC fibrosis and inflammatory response. In addition, Egr-1 was confirmed as a target gene of miR-181a. Further investigations verified that MEG3 promotes fibrosis and inflammatory response via the miR-181a/Egr-1/TLR4 axis in vitro and in vivo. These results provide new insights into the regulation between MEG3 and the miR-181a/Egr-1/TLR4 signaling pathway during DN progression.
No takes yet. Share an insight, caveat, or question.
Zha et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: